, Volume 66, Issue 12, pp 1547–1563 | Cite as

Pathophysiology, Clinical Presentation and Treatment of Gout

  • Gim Gee Teng
  • Raj Nair
  • Kenneth G. SaagEmail author
Therapy In Practice


Gout is a common form of inflammatory arthritis that has been managed primarily in general medical practices for centuries. It appears that there has been an increasing prevalence of gout over the past decades, implying a growing public health burden. Accurate diagnosis and recognition of the various stages and manifestations of gout enable realistic goal setting for management. Recent evidence suggests new risk factors and potentially refutes others. Management of gout requires characterising and modifying risk factors and associated disorders, and commonly initiating drug therapy. Pharmacotherapy of gout includes the management of acute flares with anti-inflammatory agents such as NSAIDs and glucocorticoids and long-term treatment with urate-lowering drugs. Although pharmacotherapy is generally safe and effective, there are caveats and limitations to all gout therapies. Patient non-adherence and errors with the use of drugs for gout treatment are important factors leading to medical failures. With early intervention, careful monitoring and patient education, gout is a condition that can be managed very effectively. The advent of new drugs (such as febuxostat and urate oxidase [uricase]) and enhanced understanding of the pathogenesis of gout continue to improve our therapeutic options, particularly in a subset of patients with refractory disease and those who are intolerant to currently available medications.


Colchicine Gout Allopurinol Febuxostat Acute Gout 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Assistance from the Agency for Healthcare Research and Quality (AHRQ) Centers for Education and Research on Therapeutics cooperative agreement (U18-HS10389) is acknowledged. Dr Saag has acted as a consultant and received honoraria and grants from TAP and affiliates.


  1. 1.
    Mikuls T, Farrar J, Bilker W, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005; 44: 1038–42PubMedGoogle Scholar
  2. 2.
    Mikuls TR, Curtis JR, Allison JJ, et al. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006 Mar; 33(3): 562–6PubMedGoogle Scholar
  3. 3.
    Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966 Jan 1; 1(7427): 15–8PubMedGoogle Scholar
  4. 4.
    Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005 Apr 11; 165(7): 742–8PubMedGoogle Scholar
  5. 5.
    Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995 Apr 1; 141(7): 637–44Google Scholar
  6. 6.
    Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994 Jan; 78(1): 25–9PubMedGoogle Scholar
  7. 7.
    Mikuls T, MacLean C, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937–43PubMedGoogle Scholar
  8. 8.
    Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 2002 Jul; 40(1): 37–42PubMedGoogle Scholar
  9. 9.
    Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539–50PubMedGoogle Scholar
  10. 10.
    Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995 Sep; 48(9): 1153–8PubMedGoogle Scholar
  11. 11.
    Klemp P, Stansfield SA, Castle B, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997 Jan; 56(1): 22–6PubMedGoogle Scholar
  12. 12.
    Centers for Disease Control and Prevention, National Center for Health Statistics. Vital and health statistics: current estimates from the National Health Interview Survey, 1996. Series 10. No. 200 [online]. Atlanta (GA): Department of Health and Human Services (US). Available from URL: [Accessed 2006 Aug 14]
  13. 13.
    Wallace K, Riedel A, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582–7PubMedGoogle Scholar
  14. 14.
    Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988; 41(3): 237–42PubMedGoogle Scholar
  15. 15.
    Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases: 4. Gout. Br J Rheumatol 1990 Dec; 29(6): 485–8Google Scholar
  16. 16.
    Arromdee E, Michet C, Crowson C, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403–6PubMedGoogle Scholar
  17. 17.
    Mikuls T, Farrar J, Bilker W, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 2005; 64: 267–72PubMedGoogle Scholar
  18. 18.
    Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987 Mar; 82(3): 421–6PubMedGoogle Scholar
  19. 19.
    Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002 May; 14(3): 281–6PubMedGoogle Scholar
  20. 20.
    Choi H, Atkinson K, Karlson E, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093–103PubMedGoogle Scholar
  21. 21.
    Choi H, Atkinson K, Karlson E, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277–81PubMedGoogle Scholar
  22. 22.
    Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005 Jan; 52(1): 283–9PubMedGoogle Scholar
  23. 23.
    Gibson T, Rodgers A, Simmonds H, et al. Beer drinking and its effect on uric acid. Br J Rheumatol 1984; 23: 203–9PubMedGoogle Scholar
  24. 24.
    Puig JG, Fox IH. Ethanol-induced activation of adenine nucleotide turnover: evidence for a role of acetate. J Clin Invest 1984 Sep; 74(3): 936–41PubMedGoogle Scholar
  25. 25.
    Eastmond CJ, Garton M, Robins S, et al. The effects of alcoholic beverages on urate metabolism in gout sufferers. Br J Rheumatol 1995 Aug; 34(8): 756–9PubMedGoogle Scholar
  26. 26.
    Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 1982 Dec 23; 307(26): 1598–602PubMedGoogle Scholar
  27. 27.
    Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000 Apr; 27(4): 1045–50PubMedGoogle Scholar
  28. 28.
    Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002 May 23; 417(6887): 447–52PubMedGoogle Scholar
  29. 29.
    Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000 Jan; 43(1): 103–8PubMedGoogle Scholar
  30. 30.
    Marcen R, Gallego N, Orofino L, et al. Influence of cyclosporin A (CyA) on renal handling of urate. Transpl Int 1992; 5 Suppl. 1: S81–3PubMedGoogle Scholar
  31. 31.
    Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000 May; 11(5): 974–9PubMedGoogle Scholar
  32. 32.
    Niamane R, El Hassani S, Bezza A, et al. Lead-related gout: a case report. Joint Bone Spine 2002 Jun; 69(4): 409–11PubMedGoogle Scholar
  33. 33.
    Ball G, Sorensen L. Pathogenesis of hyperuricemia in saturinine gout. N Engl J Med 1969; 280(22): 1199–202PubMedGoogle Scholar
  34. 34.
    Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004 Aug; 50(8): 2400–14PubMedGoogle Scholar
  35. 35.
    Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004 Jan; 15(1): 164–73PubMedGoogle Scholar
  36. 36.
    Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti Heart Study. J Hum Hypertens 1994 Sep; 8(9): 677–81PubMedGoogle Scholar
  37. 37.
    Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003 Oct; 42(4): 474–80PubMedGoogle Scholar
  38. 38.
    Selby JV, Friedman GD, Quesenberry CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990 Jun; 131(6): 1017–27PubMedGoogle Scholar
  39. 39.
    Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001 Jul; 19(7): 1209–15PubMedGoogle Scholar
  40. 40.
    Sundstrom J, Sullivan L, D'Agostino R, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28–33PubMedGoogle Scholar
  41. 41.
    Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002 Nov; 283(5): F1105–10PubMedGoogle Scholar
  42. 42.
    Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001 Nov; 38(5): 1101–6PubMedGoogle Scholar
  43. 43.
    Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004 Jul; 66(1): 281–7PubMedGoogle Scholar
  44. 44.
    Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001 Nov; 24(6): 691–7PubMedGoogle Scholar
  45. 45.
    Reif MC, Constantiner A, Levitt MF. Chronic gouty nephropathy: a vanishing syndrome? N Engl J Med 1981 Feb 26; 304(9): 535–6PubMedGoogle Scholar
  46. 46.
    Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002 Dec; 13(12): 2888–97PubMedGoogle Scholar
  47. 47.
    Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978 May; 88(5): 666–70PubMedGoogle Scholar
  48. 48.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 Jan 16; 287(3): 356–9PubMedGoogle Scholar
  49. 49.
    Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998 May; 8(4): 250–61Google Scholar
  50. 50.
    Becker M, Jolly M. Clinical gout and the pathogenesis of hyperuricemia. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Baltimore (MA): Williams & Wilkins, 2005: 2303–39Google Scholar
  51. 51.
    Emmerson BT. The management of gout. N Engl J Med 1996 Feb 15; 334(7): 445–51PubMedGoogle Scholar
  52. 52.
    Simkin PA. Uric acid excretion in patients with gout. Arthritis Rheum 1979 Jan; 22(1): 98–9PubMedGoogle Scholar
  53. 53.
    McPhaul JJ. Hyperuricemia and urate excretion in chronic renal disease. Metabolism 1968 May; 17(5): 430–8PubMedGoogle Scholar
  54. 54.
    Michet CJ, Evans JM, Fleming KC, et al. Common rheumatologic diseases in elderly patients. Mayo Clin Proc 1995 Dec; 70(12): 1205–14PubMedGoogle Scholar
  55. 55.
    Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970 Sep; 29(5): 461–8PubMedGoogle Scholar
  56. 56.
    Scott JT. Drug-induced gout. Baillieres Clin Rheumatol 1991 Apr; 5(1): 39–60PubMedGoogle Scholar
  57. 57.
    Pascual E, Batlle-Gualda E, Martinez A, et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999 Nov 16; 131(10): 756–9PubMedGoogle Scholar
  58. 58.
    Nakayama DA, Barthelemy C, Carrera G, et al. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984 Apr; 27(4): 468–71PubMedGoogle Scholar
  59. 59.
    O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence of tophaceous gout. Mayo Clin Proc 1975 May; 50(5): 227–8PubMedGoogle Scholar
  60. 60.
    Schumacher H. Crystal-induced arthritis: an overview. Am J Med 1996; 100: S46–52Google Scholar
  61. 61.
    Rott KT, Agudelo CA. Gout. JAMA 2003 Jun 4; 289(21): 2857–60PubMedGoogle Scholar
  62. 62.
    Puig JG, Michan AD, Jimenez ML, et al. Female gout: clinical spectrum and uric acid metabolism. Arch Intern Med 1991 Apr; 151(4): 726–32PubMedGoogle Scholar
  63. 63.
    Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis 1997 Nov; 56(11): 696–7PubMedGoogle Scholar
  64. 64.
    Simkin PA, Hoover PL, Paxson CS, et al. Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med 1979 Jul; 91(1): 44–7PubMedGoogle Scholar
  65. 65.
    Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001 Mar; 28(3): 577–80PubMedGoogle Scholar
  66. 66.
    Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002 Aug; 47(4): 356–60PubMedGoogle Scholar
  67. 67.
    Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005 Oct 4; 143(7): 499–516PubMedGoogle Scholar
  68. 68.
    Fam A. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350–5PubMedGoogle Scholar
  69. 69.
    Dessein P, Shipton E, Stanwix A, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539–43PubMedGoogle Scholar
  70. 70.
    Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004 Nov; 71(6): 481–5PubMedGoogle Scholar
  71. 71.
    Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 Mar; 65(3): 1041–9PubMedGoogle Scholar
  72. 72.
    Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64(21): 2399–416PubMedGoogle Scholar
  73. 73.
    Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: part ii management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 May 30 [Epub ahead of print]Google Scholar
  74. 74.
    Altman RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988 Sep; 15(9): 1422–6PubMedGoogle Scholar
  75. 75.
    Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995 Dec; 26(6): 682–6PubMedGoogle Scholar
  76. 76.
    Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992 Sep 10; 327(11): 749–54PubMedGoogle Scholar
  77. 77.
    Sandier DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991 Aug 1; 115(3): 165–72Google Scholar
  78. 78.
    Schumacher HR, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002 Jun 22; 324(7352): 1488–92PubMedGoogle Scholar
  79. 79.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343(21): 1520–8Google Scholar
  80. 80.
    Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar 17; 352(11): 1071–80PubMedGoogle Scholar
  81. 81.
    Fox IH, Kelley WN. Management of gout. JAMA 1979 Jul 27; 242(4): 361–4PubMedGoogle Scholar
  82. 82.
    Bonnel RA, Villalba ML, Karwoski CB, et al. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002 May; 22(4): 385–7PubMedGoogle Scholar
  83. 83.
    Sussman JS, Brozena SC, Skop N, et al. Accidental intravenous colchicine poisoning. Ther Drug Monit 2004 Dec; 26(6): 688–92PubMedGoogle Scholar
  84. 84.
    Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy: classical indications and new therapeutic uses. Eur J Med Res 2001 Apr 20; 6(4): 150–60PubMedGoogle Scholar
  85. 85.
    Roberts W, Liang M, Stern S. Colchicine in acute gout. Reassessment of risks and benefits. JAMA 1987; 257(14): 1920–2Google Scholar
  86. 86.
    Wallace S, Singer J. Review: systemic toxicity associated with the IV administration of colchicine: guidelines for use. J Rheumatol 1988; 15(3): 495–9PubMedGoogle Scholar
  87. 87.
    Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990 Jun; 19(6): 329–36PubMedGoogle Scholar
  88. 88.
    Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994 Jul; 21(7): 1325–7PubMedGoogle Scholar
  89. 89.
    Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001 Mar; 35(3): 365–8PubMedGoogle Scholar
  90. 90.
    Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988 Jun; 31(6): 803–5PubMedGoogle Scholar
  91. 91.
    Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994 Apr; 21(4): 696–9PubMedGoogle Scholar
  92. 92.
    Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987 Jun; 17(3): 301–4PubMedGoogle Scholar
  93. 93.
    Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004 Dec; 31(12): 2429–32PubMedGoogle Scholar
  94. 94.
    Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004 Dec; 24(12): 1784–92PubMedGoogle Scholar
  95. 95.
    Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004 Jun 15; 51(3): 321–5PubMedGoogle Scholar
  96. 96.
    van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of long-term antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993 Aug; 20(8): 1383–5PubMedGoogle Scholar
  97. 97.
    Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988 Oct; 26(4): 423–8PubMedGoogle Scholar
  98. 98.
    Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998 Sep; 57(9): 545–9PubMedGoogle Scholar
  99. 99.
    Takada M, Okada H, Kotake T, et al. Appropriate dosing regimen of allopurinol in Japanese patients. J Clin Pharm Ther 2005 Aug; 30(4): 407–12PubMedGoogle Scholar
  100. 100.
    Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004 Aug; 31(8): 1575–81PubMedGoogle Scholar
  101. 101.
    Hande K, Noone R, Stone W. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47–56PubMedGoogle Scholar
  102. 102.
    Fam AG, Dunne SM, Iazzetta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001 Jan; 44(1): 231–8PubMedGoogle Scholar
  103. 103.
    Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum 1991 Oct; 34(10): 1329–31PubMedGoogle Scholar
  104. 104.
    US Food and Drug Administration. Cumulative list of orphan products designated through 2006 [online]. Available from URL: [Accessed 2006 Aug 14]
  105. 105.
    Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005 May; 17(3): 319–24PubMedGoogle Scholar
  106. 106.
    Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol 1993 Dec 21; 250(3): 455–60PubMedGoogle Scholar
  107. 107.
    Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004 Oct; 23(8–9): 1117–8PubMedGoogle Scholar
  108. 108.
    Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005 Jan–Feb; 12(1): 22–34PubMedGoogle Scholar
  109. 109.
    Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 Dec 8; 353(23): 2450–61PubMedGoogle Scholar
  110. 110.
    Goldman SC. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther 2003 Aug; 3(4): 429–33PubMedGoogle Scholar
  111. 111.
    Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003 Jul–Aug; 37(7–8): 1047–54PubMedGoogle Scholar
  112. 112.
    Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002 Sep; 29(9): 1942–9PubMedGoogle Scholar
  113. 113.
    Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 1981; 26(1): 49–53PubMedGoogle Scholar
  114. 114.
    Ganson NJ, Kelly SJ, Scarlett E, et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene) glycol (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2005 Dec 2; 8(1): R12Google Scholar
  115. 115.
    Sundy JS, Becker MA, Baraf HB, et al. A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout. Arthritis Rheum 2005; 52(9): S257–S8Google Scholar
  116. 116.
    Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989 Aug 3; 321(5): 287–92PubMedGoogle Scholar
  117. 117.
    Hansen JM, Fogh-Andersen N, Leyssac PP, et al. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron 1998 Dec; 80(4): 450–7PubMedGoogle Scholar
  118. 118.
    Delaney V, Sumrani N, Daskalakis P, et al. Hyperuricemia and gout in renal allograft recipients. Transplant Proc 1992 Oct; 24(5): 1773–4PubMedGoogle Scholar
  119. 119.
    el-Gamel A, Evans C, Keevil B, et al. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients. Transplant Proc 1998 Jun; 30(4): 1127–9PubMedGoogle Scholar
  120. 120.
    McLean L. Gout in transplant recipients. In: Hochberg MC, Silman AJ, Smolen JS, et al., editors. Rheumatology.Edinburgh: Elsevier, 2003: 1914Google Scholar
  121. 121.
    Gibson T. Gout in older people. In: Hochberg MC, Silman AJ, Smolen JS, et al., editors. Rheumatology. Edinburgh: Elsevier Limited, 2003: 1926Google Scholar
  122. 122.
    Fam A. Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998; 13: 229–43PubMedGoogle Scholar
  123. 123.
    Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991 Apr; 50(4): 263–6PubMedGoogle Scholar
  124. 124.
    Terkeltaub RA. Clinical practice: gout. N Engl J Med 2003 Oct 23; 349(17): 1647–55PubMedGoogle Scholar
  125. 125.
    Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001 Oct; 60(10): 981–3PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of Medicine, Division of Clinical Immunology and Rheumatology, Center for Education and Research on Therapeutics of Musculo-skeletal DisordersUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations